bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version galera therapeutics expands series b to  million  business wire galera therapeutics expands series b to  million  sofinnova ventures joins existing lead investors nea novartis venture fund and novo ventures  november    am eastern standard time malvern pabusiness wiregalera therapeutics inc a clinicalstage biotechnology company developing transformational new treatments for cancer patients announced today it has received  million in funding from new investor sofinnova ventures bringing its series b financing total to  million sofinnova joins existing investors new enterprise associates novartis venture fund novo ventures correlation ventures enso ventures and galera angels the proceeds from the financing will be used to prepare the company’s lead product candidate gc for phase  registration studies gc is currently in a randomized placebocontrolled phase b clinical trial to evaluate its effects on the incidence duration and intensity of severe oral mucositis in head and neck cancer patients undergoing chemoradiation therapy additionally the funds will be used to further develop the company’s pipeline of selective dismutase mimetics “this investment by sofinnova is a further endorsement of galera’s team technology and clinical data generated to date and of the promise of our dismutase mimetics to transform cancer treatment” said j mel sorensen md president and ceo of galera “we look forward to expanding our development programs and demonstrating the utility of our technology in treating patients with cancer” in connection with this financing mike powell phd general partner at sofinnova will join the galera board of directors “sofinnova ventures has been intrigued for some time in galera’s scientific approach and thoughtful clinical development program” said dr powell “i am personally excited to support galera and work with mel sorensen and his team again” “we are very pleased to welcome mike to our board of directors” commented dr sorensen “his experience and long history of success in biotech is well known and we look forward to his advice and input on our technology and development programs” about oral mucositis om oral mucositis is a common debilitating side effect of radiation treatment in head and neck cancer hnc patients severe om defined by the world health organization as grade  or  om occurs in  to  percent of hnc patients receiving radiation therapy importantly severe om may result in interruptions in radiation treatment which can compromise the otherwise good prognosis for tumor control in many of these patients in addition patients with severe om suffer significant pain may develop serious infections and may be unable to eat solid food or even drink liquids further the costs of managing these side effects are substantial particularly when hospitalization andor surgical placement of peg tubes to maintain nutrition and hydration are required there is currently no drug approved to prevent or treat severe om in head and neck cancer patients about galera therapeutics inc galera therapeutics inc is a clinicalstage biotechnology company headquartered in malvern pennsylvania focused on the development of breakthrough drugs targeting oxygen metabolic pathways the companys lead compounds are highly selective small molecule dismutase mimetics that closely mimic the activity of the human superoxide dismutase enzymes while the biology of the superoxide dismutase family suggests a broad range of potential applications galera is initially focused on developing products for the prevention of radiationinduced toxicity including oral mucositis and the treatment of cancer for more information visit wwwgaleratxcom contacts sam brown incmike beyer mikebeyersambrowncom contacts sam brown incmike beyer mikebeyersambrowncom search advanced news search advanced news search log in sign up   bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one galera therapeutics inc  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       galera therapeutics inc print preview export bookmark share with colleague general information  location malvern pa  region pennsylvania  delaware valley  country us  business category cancer other  year founded   website httpwwwgaleratxcom  lead product status phase ii  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft galera therapeutics inc private company information  bloomberg july    pm et biotechnology company overview of galera therapeutics inc snapshot people company overview galera therapeutics inc a clinicalstage biotechnology company develops drugs targeting oxygen metabolic pathways the company primarily focuses on the prevention of radiationinduced toxicity including mucositis and the treatment of cancer its small molecule dismutase mimetics mimics the activity of the human superoxide dismutase enzymes the company was founded in  and is based in malvern pennsylvania  west liberty boulevardsuite malvern pa united statesfounded in  phone  wwwgaleratxcom key executives for galera therapeutics inc dr j mel sorensen md chief executive officer president and director age  dr robert a beardsley phd md founder chief operating officer and director mr joel f sussman cpa cma chief financial officer age  dr jon t holmlund md chief medical officer mr brian wood director of business development compensation as of fiscal year  galera therapeutics inc key developments galera therapeutics inc completes enrollment in phase b clinical trial with lead compound gc for treatment of oral mucositis jun   galera therapeutics inc announced that it has completed enrollment in its phase b clinical trial evaluating the efficacy safety and tolerability of gc as a treatment for reducing the incidence and duration of oral mucositis om in head and neck cancer patients receiving chemoradiation therapy gc is a novel dismutase mimetic designed to prevent the damaging effects of radiation in normal tissue by rapidly converting superoxide to hydrogen peroxide the phase b clinical trial is a double blind randomized controlled trial of  head and neck cancer patients treated with either mg or mg of gc or placebo infusion on the days they receive their radiation treatment the primary outcome measure is the duration of severe om defined as world health organization grade  or  experienced by patients receiving  weeks of radiation therapy plus cisplatin secondary endpoints include incidence of severe om galera therapeutics inc presents at boston ceo conference may  am mar   galera therapeutics inc presents at boston ceo conference may  am venue four season boston  boylston street boston ma  united states speakers robert a beardsley founder chief operating officer and director galera therapeutics inc presents at bd boston mar  pm feb   galera therapeutics inc presents at bd boston mar  pm venue the colonnade hotel  huntington avenue boston ma  united states speakers robert a beardsley founder chief operating officer and director similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact galera therapeutics inc please visit wwwgaleratxcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close enso ventures backs galera therapeutics  pe hub subscribe to pe hub wire join over  of your peers get the mustread email for pevc professionals delivered to your inbox daily — for free us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions subscribe yes no registersign in a community for professionals in private capital enso ventures backs galera therapeutics february   by iris dorbian print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub enso ventures backs galera therapeutics malvern pennsylvaniabased galera therapeutics a developer of new treatments for cancer patients has secured  million in funding from enso ventures this capital infusion brings galeras series b funding total to  million galeras other investors are new enterprise associates novartis venture fund novo ventures correlation ventures and galera angels continue reading on pe hub writes malvern pennsylvaniabased galera therapeutics a developer of new treatments for cancer patients has secured  million in funding from enso ventures this capital infusion brings galera’s series b funding total to  million galera’s other investors are new enterprise associates novartis venture fund novo ventures correlation ventures and galera angels press release malvern pa–business wire–galera therapeutics inc a clinicalstage biotech developing new treatments for cancer patients announced today it has received an additional  million in funding from enso ventures to bring its series b financing total to  million enso ventures joins existing investors new enterprise associates novartis venture fund novo ventures correlation ventures and galera angels the investment capital will be used to advance the company’s lead candidate gc in a phase b doubleblind randomized clinical trial that is currently enrolling head and neck cancer patients receiving chemoradiation therapy to prevent against oral mucositis om the proceeds will also support continued development of galera’s pipeline of selective dismutase mimetics to modulate oxygen metabolic pathways “we are delighted to have enso ventures join us” said j mel sorensen md president and ceo of galera “as we recently announced our product lead gc which is in randomized phase b clinical development was granted fast track designation for the prevention of radiationrelated oral mucositis in patients with head and neck cancer with enso’s support we will further expand the development of our dismutase mimetic portfolio” “galera’s clinical data with gc in om and the unmet need for these patients combined with the strong management and investors really drove our interest” said sergei petukhov phd partner at enso ventures “we are excited to join our fellow investors in advancing this important product and galera’s broader efforts” about oral mucositis om om is a common debilitating side effect of radiation treatment in head and neck cancer hnc patients severe om defined by the world health organization as grade  or  om occurs in  to  percent of hnc patients who receive radiation therapy importantly severe om may result in interruptions in radiation treatment which can compromise the otherwise good prognosis for tumor control in many of these patients in addition patients suffer significant pain may develop serious infections and may be unable to eat solid food or even drink liquids further the costs of managing these side effects are substantial particularly when hospitalization andor surgical placement of peg tubes to maintain nutrition and hydration is required there is currently no drug approved to prevent or treat severe om in head and neck cancer patients about galera therapeutics inc galera therapeutics inc is a clinicalstage biotechnology company headquartered in malvern pa focused on the development of breakthrough drugs targeting oxygen metabolic pathways the company’s lead compounds are highly selective small molecule dismutase mimetics that closely mimic the activity of the human superoxide dismutase enzymes while the biology of the superoxide dismutase family suggests a broad range of potential applications galera is initially focusing its development on the prevention of radiationinduced toxicity including mucositis and the treatment of cancer for more information visit wwwgaleratxcom print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub enso ventures backs galera therapeutics malvern pennsylvaniabased galera therapeutics a developer of new treatments for cancer patients has secured  million in funding from enso ventures this capital infusion brings galeras series b funding total to  million galeras other investors are new enterprise associates novartis venture fund novo ventures correlation ventures and galera angels continue reading on pe hub writes find new deal opportunities supercharge your fundraising efforts and track top managers with vcj get your free trial or subscribe now sign up to our newsletter receive updates from our pe hub wire and top stories of the week newsletters first name last name email address us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions you are now subscribed to the pehub wire and top stories of the week newsletters buyouts insiderargosy group llc produces several free newsletters that are sent directly to the email you provide at registration namely pe hub wire pe hub canada wire pe hub wire top story of the week buyouts daily and vcj alert to enable us to keep providing these services free of charge we reserve the right to contact you with special invitations to sample or purchase private equityrelated products by submitting this free subscription request for any of these products you are also consenting to this communication should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email this will discontinue both the special invitations mentioned previously as well as your subscription to the weekly newsletter the information you provide will be safeguarded by argosy group llcbuyouts insider the company’s subsidiaries may use it to keep you informed of relevant products and services we occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you as an international group we may transfer your data on a global basis for the purposes indicated above we will never share your email or contact details with any outside company however should you have any questions please do not hesitate to contact us email protected top posts kkr to buy nature’s bounty from carlyle by luisa beltran blackrock leads funding round for fintech platform icapital by iris dorbian platinum equity to buy united site services by luisa beltran the pe hub podcast episode two by staff report private equity jobs of the week priceline kpmg novaquest are hiring by eamon murphy the carveout curveball by pehublogger network raymond james expands team with new hire by iris dorbian blackstone acquires clarion events from providence by iris dorbian galera therapeutics inc company profile  outlook business segments competitors goods and services swot and financial analysis    about us blog contact us faq  usd eur gbp usd ▼ usd eur gbp € eur  usd £ gbp rest of world us toll free  advanced price from €eurusd£gbp view pricing home  categories  company reports select a format  €eurusd£gbp single user electronic pdf  this is a single user license allowing one specific user access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp cdrom  the report will be shipped to you in cd rom format  €eurusd£gbp hard copy  a printed copy of the report will be shipped to you  €eurusd£gbp site license electronic pdf  this is a site license allowing all users within a given geographical location of your organisation access to the product the report will be emailed to you the report is sent in pdf format  €eurusd£gbp enterprisewide electronic pdf  this is an enterprise license allowing all employees within your organisation access to the product the report will be emailed to you the report is sent in pdf format  add to basket order by fax need a quote  our clients have a question email us view faqs recently viewed products partner of research and marketsvaccinating  children in  why choose research and markets worlds largest selection trusted by the best customer focused safe  secure research and markets orders department was very responsive and helpful thank you for making this a great purchase experience read more ms keiko tokuda marketing manager eventbrite galera therapeutics inc company profile  outlook business segments competitors goods and services swot and financial analysis id  company profile november   pages lng analysis description table of contents formats  of  login to access executive summary printer friendly printable pdf brochure send to a friend “galera therapeutics inc company profile” is a complete analysis of the company’s operations strategies outlook and historic performance the research work analyzes key strategies in current market conditions swot profile future plans and projects being planned by the companycurrent operations potential segments along with its key advantages which provide an edge over its competitors are detailed galera therapeutics inc’s business description products services and projects are detailed in the report further key brands operating locations subsidiaries and affiliates are analyzed in detailgalera therapeutics inc company profile competitors are listed along with ceo’s annual outlook statement key employees organization structure and contact information is analyzed further ma deals expansion and asset purchase plans of the company are also detaileddetailed swot and financial analysis of galera therapeutics inc are included in the research work key events in the history of the company and all latest updates of the company are provided note product cover images may vary from those shown  of  login to access executive summary printer friendly printable pdf brochure send to a friend  table of contents list of tables list of figures galera therapeutics inc snapshot galera therapeutics inc overview business strategies and outlook stock information galera therapeutics inc locations subsidiaries and affiliates operating areas subsidiaries affiliate jv companies galera therapeutics inc swot profile strengths weaknesses opportunities threats galera therapeutics inc outlook statement galera therapeutics inc history galera therapeutics inc business operation structure business overview operations by segments galera therapeutics inc products and services key products key services galera therapeutics inckey competitors galera therapeutics inc management and key employees galera therapeutics inc financial analysis and statements income statements cash flow statements balance sheet galera therapeutics inc contact information galera therapeutics inc recent developments appendix about the author sources and research methodologyfinancial analysis will be provided for the latest year as reported by the companytable  galera therapeutics inc key snapshottable  galera therapeutics inc geographic locationstable  key events and historytable  galera therapeutics inc income statementstable  galera therapeutics inc balance sheettable  cash flow statementsfigure  swot analysisfigure  financial statements note product cover images may vary from those shown  of  loading  of  note product cover images may vary from those shown related products boulevard holdings inc  strategy swot and corporate finance report  swot analysis january  from €eurusd£gbp boulevard holdings inc  travel and tourism  company profile swot  financial analysis  company profile july  from €eurusd£gbp abeona therapeutics inc abeo  financial and strategic swot analysis review  swot analysis may  from €eurusd£gbp g therapeutics inc company profile  outlook business segments competitors goods and services swot and financial analysis  company profile november  from €eurusd£gbp pervasis therapeutics inc company profile outlook business segments competitors goods and services swot and financial analysis  company profile november  from €eurusd£gbp pearl therapeutics inc company profile outlook business segments competitors goods and services swot and financial analysis  company profile november  from €eurusd£gbp padlock therapeutics inc company profile outlook business segments competitors goods and services swot and financial analysis  company profile november  from €eurusd£gbp regulus therapeutics inc company profile outlook business segments competitors goods and services swot and financial analysis  company profile november  from €eurusd£gbp sapphire therapeutics inc company profile outlook business segments competitors goods and services swot and financial analysis  company profile november  from €eurusd£gbp relmada therapeutics inc company profile outlook business segments competitors goods and services swot and financial analysis  company profile november  from €eurusd£gbp close galera therapeutics inc company profile  outlook business segments competitors goods and services swot and financial analysis close ask a question required information product galera therapeutics inc company profile  outlook business segments competitors goods and services swot and financial analysis your question your contact details title mr mrs dr miss ms prof first name last name email address country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe phone number                                                                                                                                                                                                                                    we request your telephone number so we can contact you in the event we have difficulty reaching you via email we aim to respond to all questions on the same business day close send to a friend  required information friends details full name email address message to friend your contact details full name email address close request a quote please complete the below form and click send request to obtain a pdf quotation and order form this document will be available for immediate download and will also be emailed to you  required information your address address  address  address  city postalzip code country please select  united states united kingdom germany canada australia  afghanistan albania algeria american samoa andorra angola anguilla antarcticacasey antarcticascott antigua and barbuda argentina armenia aruba ascension island ashmore and cartier islands atlantic east atlantic west australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana brazil british virgin islands brunei bulgaria burkina faso burma burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island clipperton island cocos keeling islands colombia comoros congo cook islands costa rica croatia cuba curaco cyprus czech republic democratic republic of congo denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands islas malvinas faroe islands fiji islands finland france french guiana french polynesia gabon gambia gaza strip georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy ivory coast ivory coast cote divoire jamaica japan jordan kazakhstan kenya kiribati kosovo kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte islands mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk islands north korea northern ireland northern marianas norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines poland portugal puerto rico qatar reunion romania russia rwanda saint christopher nevis saint helena saint kitts and nevis saint lucia saint martin saint vincent and the grenadines samoa san marino sao tome saudi arabia scotland senegal serbia serbia and montenegro seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka sudan suriname swaziland sweden switzerland syria tahiti taiwan tajikistan tanzania thailand togo trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city holy see venezuela vietnam virgin islands wallis and futuna west bank west indies western sahara yemen yugoslavia zaire zambia zimbabwe state your details title mr mrs dr miss ms prof first name last name organisation email address phone number                                                                                                                                                                                                                                    po number if applicable product format license format properties price single user electronic pdf the report will be emailed to you the report is sent in pdf format this is a single user license allowing one specific user access to the product €eurusd£gbp cdrom the report will be shipped to you in cd rom format €eurusd£gbp hard copy a printed copy of the report will be shipped to you €eurusd£gbp site license electronic pdf the report will be emailed to you the report is sent in pdf format this is a site license allowing all users within a given geographical location of your organisation access to the product €eurusd£gbp enterprisewide electronic pdf the report will be emailed to you the report is sent in pdf format this is an enterprise license allowing all employees within your organisation access to the product €eurusd£gbp  the price quoted above is only valid for  days please submit your order within that time frame to avail of this price as all prices are subject to change transforming the science and treatment of cancer  galera recent newsgalera therapeutics completes enrollment in phase b clinical trial with lead compound gc for treatment of oral mucositis transforming the science and treatment of cancer our vision galera therapeutics is discovering and developing novel mechanismbased therapies that have the potential to improve both treatment and outcomes for patients with cancer learn more  preventing oral mucositis we believe that precisely targeting oxygen metabolic pathways offers unique and powerful strategies for treating cancer and addressing treatmentrelated side effects learn more  the science of superoxide dismutase mimetics  the cornerstone of our work is the recognition that oxygen metabolic pathways play important roles in human biology and disease learn more  management  galera management mel sorensen md president and chief executive officer dr sorensen is president and chief executive officer and board director of galera therapeutics dr sorensen is a medical oncologist who has spent  years each in patient care including his oncology fellowship at the mayo clinic in academia at the national institutes of health in leadership positions in clinical development in the pharmaceutical industry glaxosmithkline and bayer and as president  ceo of private venturefunded biotechs including ascenta therapeutics and galera therapeutics he also serves as chairman of other biotech companies including oncofusion therapeutics at ascenta dr sorensen raised approximately  million in private financing and venture debt and secured global and regional deals for its three programs operationally in about five years ascenta advanced two unrelated preclinical programs into broad clinical testing managed multiple clinical trials and developed an rd presence in china dr sorensen is an advisor to the biomarkers consortium of the national institutes of health robert a beardsley phd chief operating officer dr beardsley is a founder chief operating officer and board director of galera therapeutics prior to galera he served as ceo at metabolic solutions development corporation and kereos as acting ceo at metaphore pharmaceuticals and in a variety of roles at confluence life sciences simile investors biostrategies group and vector securities international in addition dr beardsley served on the boards of a number of other public and private life science firms including collagenex pharmaceuticals bioseek and kempharm he has an mba in finance from the university of chicago and a phd in biochemical engineering from the university of iowa dennis p riley phd chief scientific officer dr riley cofounded galera therapeutics and has been galera’s cso since the founding prior to galera therapeutics dr riley was senior vice president at kereos and prior to that was vp of research at metaphore pharmaceuticals dr riley spent much of his career at monsanto rising to a senior science fellow and manager of metalmediated chemistry dr riley is an adjunct professor of chemistry at washington university after graduating cum laude from heidelberg college with majors in chemistry and mathematics he earned his phd at ohio state university followed by postdoctoral training at the university of chicago he was elected a fellow of the american association for the advancement of science in  elected chairperson and organizer of the  gordon research conference on inorganic chemistry was the recipient of the acs st louis section’s “chemist of the year” award for  was the recipient of the  ohio state university devon meek memorial lectureship is the recipient of the  herman s bloch memorial lectureship at the university of chicago and was lecturer at the st peter a leermakers symposium at wesleyan university in may  he has over  us patents granted and has published over  primary scientific articles jon t holmlund md chief medical officer dr holmlund is a medical oncologist who has served galera as chief medical officer since october  he has over  years’ experience in oncology drug development in senior positions in industry cmo of ascenta therapeutics vp of development at isis now ionis pharmaceuticals as a consultant to large and small biopharmaceutical companies and as a senior investigator in the national cancer institute’s cancer therapy evaluation program and biological response modifiers program he received his md from suny buffalo and completed postgraduate training in internal medicine and medical oncology at george washington university medical center washington dc arthur fratamico rph chief business officer mr fratamico is a registered pharmacist with over  years of experience in the pharmaceutical industry and has been our chief business officer since january  prior to joining galera mr fratamico served as chief business officer of vitae pharmaceuticals until its sale to allergan prior to vitae pharmaceuticals he has held similar executive roles with a number of biotechnology companies leading their business development efforts including facilitating the sales of gemin x pharmaceuticals and mgi pharma in addition to being responsible for numerous licensing transactions and acquisitions he also directed corporate strategy and managed external corporate communications he also served in several senior marketing product planning and new product development positions mr fratamico earned a bachelor’s degree in pharmacy from the philadelphia college of pharmacy and science and an mba from drexel university joel sussman cpa chief financial officer mr sussman is a financial management consultant who serves as chief financial officer for earlystage companies his present and former clients include numerous venture capitalbacked life sciences companies before beginning his consulting practice in  he had  years’ experience as chief financial officer andor treasurer of public and private technology and healthcare companies in  he joined a client as cfo and took it public resuming his consulting practice in  after its sale he has an undergraduate degree from yale an mba degree from the wharton school of the university of pennsylvania and is a licensed certified public accountant stephen ross chief commercial officer mr ross is a year veteran on the global sales marketing and commercial strategy side of the healthcare industry before joining galera therapeutics he served for eight years as chief commercial officer of ikaria inc a leading critical care drug manufacturer ikaria was acquired by mallinckrodt for  billion in  mr ross also held many commercial roles over a year period with glaxosmithkline including sr vice president of the uk subsidiary’s  billion specialty products division general manager of gsk’s irish subsidiary and marketing leadership of gsk’s billion dollar us oncology portfolio over the course of his career mr ross has developed a deep understanding of hospital specialty products particularly cancer therapeutics and supportive care products he holds an undergraduate degree in economics from brigham young university and an mba in marketing and finance from the wharton school of the university of pennsylvania board of directors  who we are  board of directors  galera board of directors james barrett phd chair dr barrett joined new enterprise associates nea in  as a general partner specializing in biotechnology he works with members of nea’s healthcare investment group on medical devices healthcare information systems and healthcare service companies prior to joining nea jim served as founder chairman and ceo of sensors for medicine and science where he remains chairman in addition to galera therapeutics jim currently serves on the boards of several other biotechpharma companies thomas dyrberg md dmsc dr dyrberg is managing partner at novo as he is a member of the boards of directors of delenex therapeutics ag nuvelution pharma inc ophthotech corporation panoptica inc and veloxis pharmaceuticals as dr dyrberg held research positions at the hagedorn research institute denmark and at the scripps research institute la jolla ca usa in  he joined novo nordisk as initially working in health care discovery on various aspects of diabetes immunology and pathogenesis and from  in health care clinical drug development dr dryberg attended the university of copenhagen where he obtained an md degree and a dmsc degree campbell murray md dr murray is a managing director for the novartis venture funds in cambridge ma usa prior to joining the fund he worked at the novartis institutes for biomedical research as the director of special projects and as a physician in auckland new zealand campbell is a new zealand trained physician kauffman fellow and holds an mba from harvard business school and an mpp public policy from the john f kennedy school of government where he was a knox fellow and rotary ambassadorial scholar campbell serves on the boards of aerpio therapeutics alios biopharma annexon bionano genomics galera therapeutics imaginab and neurovance mike powell phd dr powell joined sofinnova in  and svp x is his seventh sofinnova fund he has  years of experience including  years of rd before entering the venture community dr powell has been involved in more than  clinical programs and is the author of  publications and books including a page treatise on vaccine design before joining sofinnova he was group leader of drug delivery at genentech as well as director of product development at cytel before this he was senior scientist and project team leader at syntex research dr powell received his phd in physical chemistry from the university of toronto and carried out postdoctoral studies in bioorganic chemistry at the university of california as a national science and engineering research council scholar henry skinner phd dr skinner is a managing director for the novartis venture funds in cambridge ma usa prior to the novartis venture funds he worked as executive director and global head strategic alliances therapeutics and head strategic alliances technologies at the novartis institutes for biomedical research where he led a team responsible for identification negotiation and management of collaborations and licenses for novartis’ therapeutic areas as well as the technology areas prior to joining novartis he was ceo of selectx pharmaceuticals and president and ceo of neogenesis pharmaceuticals which was acquired by scheringplough he was also director of technology acquisitions for pharmacia  upjohn and pharmacia managing business development and licensing for pharmacia’s research platforms and therapeutic areas worldwide and director of business development at lexicon genetics he was a postdoctoral fellow at baylor college of medicine in the department of human and molecular genetics and earned his phd in microbiology and ms in biochemistry from the university of illinois henry serves on the board of avila and works with cylene forma and merus frank torti md dr torti joined nea in  and focuses on investments in biopharmaceuticals medical devices and healthcare services he has been actively involved in the firm’s private and public investments in healthcare including peplin acquired by leo pharma citic pharmaceuticals acquired by shanghai pharmaceuticals alimera sciences cadence pharmaceuticals dermira galera therapeutics neotract novast pharmaceuticals rigel pharmaceuticals and solta medical dr torti received his md from the university of north carolina school of medicine his mba with distinction from harvard business school and his ba with highest honors from the university of north carolina where he was a morehead scholar mel sorensen md dr sorensen is president and chief executive officer of galera therapeutics dr sorensen is a medical oncologist who has spent  years each in patient care including his oncology fellowship at the mayo clinic in academia at the national institutes of health in leadership positions in clinical development in the pharmaceutical industry glaxosmithkline and bayer and as president  ceo of private venturefunded biotechs including ascenta therapeutics and galera therapeutics he also serves as chairman of other biotech companies including oncofusion therapeutics at ascenta dr sorensen raised approximately  million in private financing and venture debt and secured global and regional deals for its three programs operationally in about five years ascenta advanced two unrelated preclinical programs into broad clinical testing managed multiple clinical trials and developed an rd presence in china dr sorensen is an advisor to the biomarkers consortium of the national institutes of health robert a beardsley phd dr beardsley is a founder and chief operating officer of galera therapeutics prior to galera he served as ceo at metabolic solutions development corporation and kereos as acting ceo at metaphore pharmaceuticals and in a variety of roles at confluence life sciences simile investors biostrategies group and vector securities international in addition dr beardsley served on the boards of a number of other public and private life science firms including collagenex pharmaceuticals bioseek and kempharm he has an mba in finance from the university of chicago and a phd in biochemical engineering from the university of iowa management  who we are  transforming the science and treatment of cancer  galera recent newsgalera therapeutics completes enrollment in phase b clinical trial with lead compound gc for treatment of oral mucositis transforming the science and treatment of cancer our vision galera therapeutics is discovering and developing novel mechanismbased therapies that have the potential to improve both treatment and outcomes for patients with cancer learn more  preventing oral mucositis we believe that precisely targeting oxygen metabolic pathways offers unique and powerful strategies for treating cancer and addressing treatmentrelated side effects learn more  the science of superoxide dismutase mimetics  the cornerstone of our work is the recognition that oxygen metabolic pathways play important roles in human biology and disease learn more  ﻿ galera therapeutics inc pharmaceuticals  healthcare deals and alliances profile ken research   agriculture and animal care agriculture equipment agricultural implements combine harvesters rotavators tillers tractors animal care animal feed animal health pet crop protection agriculture chemical fertilizer net wrap protected cultivation farming field crops fishing fruits and vegetables irrigation plantations seed conventional seed hybrid seed   automotive transportation and warehousing automotive and automotive components auto components automobiles car rental hybrid vehicles lubricant used vehicles general transportation airlines travel aviation railway travel intermediaries logistics and shipping courier packaging transportation value added services warehousing   banking financial services and insurance banking atm banknote online banking retail banking financial services credit rating financial advisory investment banking payments private equity remittance stock broking vending machines wealth management insurance general insurance health insurance life insurance motor insurance reinsurance loans and advances housing loan online loans vehicle loan   consumer products and retail baby care baby apparel and footwear baby equipment baby food baby personal care maternity products consumer electronics audio systems camera computers and peripherals large appliances lighting mobile phone and accessories consumer services ondemand services cosmetics and personal care breath fresheners cosmeceuticals disposable consumer products eye care flavors  fragrance hair care herbal products hygiene nail care oral care personal accessories skin care toiletries home and office furnishings air purifier and freshner bathing furniture gardening home appliances kitchenware mattress stationery water purifier luxury goods artwork products cruises and yachts gems and jewelry luggage and bags watch sporting equipments bicycle golf textile apparel and footwear apparel and footwear apparel and textile athletic apparel innerwear wholesale and retail departmental stores franchisee grocery store cards   defense and security defense aerospace products air force aircraft components army automation and modernization combat vehicles mro services navigational instruments navy security devices access control cyber security fire alarm intrusion alert it security video survelliance weapon ballistic protection military ammunition   education and recruitment education corporate education e learning higher education pre primary primary secondary teacher training test preparation vocational education recruitment   energy and utilities clean technology biofuel carbon fibre hydro solar waste management wind gas lng natural gas shale gas oil drilling and exploration eor equipments and services fuel dispenser midstream naphtha octg oil storage petroleum fuels refining upstream power electricity generation and transmission inverter and ups nuclear power components reservoir development thermal   food beverage and tobacco alcoholic beverages beer cider country liquor imfl wine dairy products butter cheese cream dairy products milk skim milk powder soymilk whey powder whole milk powder yogurt and ice cream food services catering food kiosks quick service restaurant general food confectionary cooking oil dry fruits flour products food ingredients frozen food gluten organic food packaged food processed food ready to eat spice sugar vending machine non alcoholic beverages bottled water carbonated soft drinks energy  sports drink hot beverage iced tea and coffee juice tobacco products cigar cigarette hookah smokeless tobacco   healthcare diagnostics diagnostic lab in vitro diagnostics sleep apnea general healthcare biotechnology healthcare it home healthcare hospitals and clinics old age homes surgery wellness wound care medical devices aesthetic laser biopsy devices bone growth stimulators cardiovascular consumables dental equipment diagnostic imaging ent neurology devices orthopedic pharmaceuticals active pharmaceutical ingredient blood product crams diabetes nutritional and dietary supplements osteoporosis otc drug pharmaceutical pharmacy stores prescribed drug respiratory vaccine   manufacturing and construction construction materials aluminum bricks and blocks cement ceramics electric material explosives glass hardware materials marbles and granite paper refractory materials roofing products sanitaryware steel windows and doors wood industrial engineering industrial automation interior designing infrastructure construction shipbuilding machinery and parts construction machinery elevator and escalator home automation machinery components pipe and valve power tools pump stamping machine tapes other manufacturing activities msme real estate commercial facility management green building hotel real estate consultancy real estate investment trust residential retail   media and entertainment advertising online advertising outdoor advertising films and animation music stores  instruments online music theater video rental gaming and gambling casino online gaming theme park toys video game information services newspaper and magazines intelligence and analytics marketing public publishing relations tourism medical tourism tv radio and broadcasting cable iptv pay tv   metal mining and chemicals chemicals adhesive and sealants coating fine chemicals organic chemicals paint petrochemicals plastics polymer materials rubber specialty chemicals metals  minerals ferrous metals non ferrous metals mining bauxite mining coal mining copper mining gold mining iron ore mining other mining   public sector and administration legal services public services religion funeral wedding   technology and telecom it and ites e commerce embeded systems hosting ict process outsourcing semiconductor software and digital content technology hardware telecommunications and networking cloud services mobile broadband mvas networking and communication equipment smartphone wireless wireline advanced search  call us now     toll free  query  kenresearchcom  login email address password forgot the password  keep me loggedin new here  join us thanks for registering with us please login your your account register  please be patient your registration is in progress it will take few moment name  password  confirm password  phone no  email id    provide corporate academic email id only in case of personal email id provide linkedin profile link in the company address company name    company name and address is required for invoicing process company address    company name and address is required for invoicing process state  country  select afghanistan algeria argentina australia austria bahamas bangladesh barbados belgium belize bermuda bolivia brazil brunei darussalam bulgaria canada czech republic chile china colombia costa rica croatia denmark dominican republic ecuador egypt estonia england finland france germany guatemala greece honduras hong kong hungary iceland ireland india indonesia iran ireland israel italy jamaica japan jordan kenya kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia maldives malta mexico monaco morocco nepal netherlands new zealand norway pakistan panama paraguay peru philippines poland portugal puerto rico qatar romania russia saudi arabia scotland singapore slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand turkey uganda ukraine united arab emirates united kingdom united states venezuela vietnam yugoslavia wales others pin code  validation   if validation code does not match please refresh the page subscribe for the newsletter     forgot password  email id      forgot password  email id      about us services categories news contact us you are here  home  healthcare  pharmaceuticals select a format single user license usd  inr  site license usd  inr  corporate user license usd  inr  alternatively request a quote thanks for submitting the form our marketing team will connect back to you for the budget constraint request a quote name  designation  email  phone no  company name  company url  current budget  security code    if validation code does not match please refresh the page report title  galera therapeutics incpharmaceuticals  healthcaredeals and alliances profile quote request for license type license type   license rights price single user license  electronic pdf for single user no print no copy only internal use usd  site license  electronic pdf for site use across authorised users in a single location with print and copy rights only internal use usd  enterprise wide license  electronic pdf for enterprise wide across multiple locations with print and copy rights only internal use usd    request a customized research thanks for letting us know your requirement our research team will connect back to you for the bespoke requirement request a customized research name  designation  email  phone no  company name  company url  current budget  report title  galera therapeutics incpharmaceuticals  healthcaredeals and alliances profile requirement  timeline  in working days   security code    if validation code does not match please refresh the page quote request for license type license type   license rights price single user license  electronic pdf for single user no print no copy only internal use usd  site license  electronic pdf for site use across authorised users in a single location with print and copy rights only internal use usd  enterprise wide license  electronic pdf for enterprise wide across multiple locations with print and copy rights only internal use usd    request for sample report thank you for submitting the form the concerned team will will get back to you within next  hours thank you for downloading the sample report request for sample report report title  galera therapeutics incpharmaceuticals  healthcaredeals and alliances profile name  designation  email  phone no  company name  company url  security code    if validation code does not match please refresh the page requirement    newsletter by category for regular updates on our latest research reports subscribe newsletter interested areas agriculture and animal care automotive transportation and warehousing banking financial services and insurance consumer products and retail defense and security education and recruitment energy and utilities food beverage and tobacco healthcare manufacturing and construction media and entertainment metal mining and chemicals public sector and administration technology and telecom faq clientele recent viewed reports why ken reasearch compare reports to make purchase decision prepaid account to get you valuable discount customized research for business study purchase the section to save on next research testimonials this is with regards to your report on india pvc pipes and fitting market outlook industry outlook to  this is a very well written report and accept my compliments on the same  mohit mittal consultant kpmg advisory services i am pleased to see the very useful and productive information in the reportvery well structured great presentation reflect professionalism in your research studies mustafa masood financial analyst  coldwell banker riyadh while we still are studying and analysing your reports about vietnam  thailand we would like to convey to your research team that they have done a very good job in compiling so much of information together we hope to see more of such well researched reports all the best  keep it up  prashant bhagwatgeneral manager mahindra we would like to appreciate ken research for their great efforts and wonderful support in providing the market intelligence report for itpc the information statistics and research are well understandable and very clear to the point we are happy with ken research for their good client service ontime delivery of the report and as said the report itself thank you ken research for bringing the valuable output for us we would be looking forward to have more research with you in the near future wish you a success in your business jestin mathew indonesian trade promotion center the report was very interesting and useful for me marketing manager western union business solutions galera therapeutics incpharmaceuticals  healthcaredeals and alliances profile products id  gdphd  pages   march   region north america  globaldata  equity research report   request for sample report  previous  next summary scope list of figure list of table licence rights products executive summary galera therapeutics inc galera therapeutics is a clinical stage biotechnology company that develops drugs and targeting oxygen metabolic pathways the company also concentrates its development on the prevention of radiationinduced toxicity including mucositis and the treatment of cancer its lead technology includes a portfolio of small molecule superoxide dismutase mimetics galera therapeutics small molecule dismutase mimetics copies the human superoxide dismutase enzyme activities and overcome the deficiency the company targets gc to reduce the incidence intensity and duration of severe oral mucositis galera therapeutics is headquartered in malvern pennsylvania the usgalera therapeutics incpharmaceuticals  healthcaredeals and alliances profile provides you comprehensive data and trend analysis of the companys mergers and acquisitions mas partnerships and financings the report provides detailed information on mergers and acquisitions equitydebt offerings private equity venture financing and partnership transactions recorded by the company over a five year period the report offers detailed comparative data on the number of deals and their value categorized into deal types subsector and regionsglobaldata derived the data presented in this report from proprietary inhouse pharma etrack deals database and primary and secondary researchscopefinancial dealsanalysis of the companys financial deals including mergers and acquisitions equitydebt offerings private equity venture financing and partnerships deals by yearchart and table displaying information encompassing the number of deals and value reported by the company by year for a five year period deals by typechart and table depicting information including the number of deals and value reported by the company by type such as mergers and acquisitions equitydebt offering etc deals by regionchart and table presenting information on the number of deals and value reported by the company by region which includes north america europe asia pacific the middle east and africa and south and central america deals by subsectorchart and table showing information on the number of deals and value reported by the company by subsector major dealsinformation on the companys major financial deals each such deal has a brief summary deal type deal rationale and deal financials and target companys major public companies key financial metrics and ratios business descriptiona brief description of the companys operations key employeesa list of the key executives of the company important locations and subsidiariesa list and contact details of key centers of operation and subsidiaries of the company key competitorsa list of the key competitors of the company key recent developmentsa brief on recent news about the companyreasons to buyget detailed information on the companys financial deals that enable you to understand the companys expansiondivestiture and fund requirements the profile enables you to analyze the companys financial deals by region by year by business segments and by type for a five year periodunderstand the companys business segments expansion  divestiture strategy the profile presents deals from the companys core business segments perspective to help you understand its corporate strategyaccess elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company detailed information on major recent deals includes a summary of each deal deal type deal rationale deal financials and target companys key financial metrics and ratiosequip yourself with detailed information about the companys operations to identify potential customers and suppliers the profile analyzes the companys business structure locations and subsidiaries key executives and key competitorsstay uptodate on the major developments affecting the company recent developments concerning the company presented in the profile help you track important eventsgain key insights into the company for academic or business research key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needsnote some sections may be missing if data is unavailable for the company contact us ken research ankur gupta head marketing  communications ankur  kenresearchcom  wwwkenresearchcom table of contents table of contents  list of tables  list of figures  galera therapeutics inc pharmaceuticals  healthcare deals by year  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by type  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by region  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by therapy area  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals summary  to ytd   galera therapeutics inc pharmaceuticals  healthcare deal details  venture financing  galera therapeutics raises additional usd million in series b financing  galera therapeutics raises additional usd million in series b financing  galera therapeutics raises usd million in series b financing  galera therapeutics raises usd million in venture financing  galera therapeutics raises us million in series a financing  galera therapeutics raises us million in venture financing  galera therapeutics raises us million in series  financing  galera therapeutics inckey competitors  key employees  locations and subsidiaries  head office  appendix  methodology  about globaldata  contact us  disclaimer  list of figures galera therapeutics inc pharmaceuticals  healthcare deals by type  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by year  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by region  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by therapy area  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by year  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by type  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by region  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by therapy area  to ytd   list of tables galera therapeutics inc pharmaceuticals  healthcare key facts  galera therapeutics inc pharmaceuticals  healthcare deals by year  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by type  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals by region  to ytd   galera therapeutics inc deals by therapy area  to ytd   galera therapeutics inc pharmaceuticals  healthcare deals summary  to ytd   galera therapeutics raises additional usd million in series b financing  galera therapeutics raises additional usd million in series b financing  galera therapeutics raises usd million in series b financing  galera therapeutics raises usd million in venture financing  galera therapeutics raises us million in series a financing  galera therapeutics raises us million in venture financing  galera therapeutics raises us million in series  financing  galera therapeutics inc key competitors  galera therapeutics inc key employees  single user license report can be used by individual purchaser only site license report can be shared by unlimited users within one corporate location eg a regional office corporate user license report can be shared globally by unlimited users within the purchasing corporation eg all employees of a single company to know more information on purchase by section please send a mail to query  kenresearchcom   galera therapeutics inc deal analysis mergers acquisitions asset purchases asset divestitures company divestitures equity offerings capital raising debt offerings ipos initial public offering private placement private investment in public equities secondary offerings followon offerings debt private placement public debt placement partnerships joint venture licensing agreements comarketing agreements upfront payment milestone payment phases clinical trials private equity venture capital pevc asset finance project finance tax equity financing bond financing lease financing new build financing deal analysis by marketsector deal analysis by geography deal analysis by deal types key employees locations and subsidiaries competitors recent news company overview key facts deals by year deal details recent developments significant developments related products in vertical vietnam nutraceuticals market outlook to   rising demand for infant products and probiotic supplements to foster future growth ken research  page   july  read more thailand nutraceuticals market outlook to   rising trust over herbal ingredients with increasing use of ginseng in functional foods to foster future growth ken research  page   july  read more korea nutraceuticals market outlook to   rising trust over herbal ingredients with increasing use of ginseng in functional foods to foster future growth ken research  page   july  read more other reports by publisher leukemia diagnostic testsmedical devices pipeline assessment  globaldata  page   june  read more positron emission tomography pet systemsmedical devices pipeline assessment  globaldata  page   june  read more nucleus replacementmedical devices pipeline assessment  globaldata  page   june  read more company home about us services categories news contact us careers rss feeds quick links blog industry reports equity research reports country research reports deal directory publishers upcoming publication latest publications other links discounted reports discount coupons media releases testimonial terms  conditions privacy policy disclaimer faqs site map contact us ken research pvt ltd a tower b spaze i tech business park sohna road sector  nbspnbspnbspnbspnbspgurgaon haryana   india   follow us wish to know more about us download company brochure for further enquiry careers apply for job your resume has been successfully received hr will connect you within  days in case your resume gets shortlisted come on we need you make a start to an incredible career applicant name job function job function market research associate market research analyst seo executive content writer web designer hr specialist total experience year year            months months year              skills email id  notice period current ctc  expected ctc ctcmonthly expected ctcmonthly phone number validation   if validation code does not match please refresh the page   know how we roll our services engage with us query  kenresearchcom thanks for submitting the form please refer to the attached brochure company brochure name email company name select country select afghanistan algeria argentina australia austria bahamas bangladesh barbados belgium belize bermuda bolivia brazil brunei darussalam bulgaria canada czech republic chile china colombia costa rica croatia denmark dominican republic ecuador egypt estonia england finland france germany guatemala greece honduras hong kong hungary iceland ireland india indonesia iran ireland israel italy jamaica japan jordan kenya kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia maldives malta mexico monaco morocco nepal netherlands new zealand norway pakistan panama paraguay peru philippines poland portugal puerto rico qatar romania russia saudi arabia scotland singapore slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand turkey uganda ukraine united arab emirates united kingdom united states venezuela vietnam yugoslavia wales others phone no validation   if validation code does not match please refresh the page thanks for submitting the form the concerned team will respond to your query in the next  hours engage with us name designation email phone no company name company url select country select afghanistan algeria argentina australia austria bahamas bangladesh barbados belgium belize bermuda bolivia brazil brunei darussalam bulgaria canada czech republic chile china colombia costa rica croatia denmark dominican republic ecuador egypt estonia england finland france germany guatemala greece honduras hong kong hungary iceland ireland india indonesia iran ireland israel italy jamaica japan jordan kenya kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia maldives malta mexico monaco morocco nepal netherlands new zealand norway pakistan panama paraguay peru philippines poland portugal puerto rico qatar romania russia saudi arabia scotland singapore slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand turkey uganda ukraine united arab emirates united kingdom united states venezuela vietnam yugoslavia wales others requirements comments validation   if validation code does not match please refresh the page net wrap  store cards  dry fruits  ondemand services  online music  bicycle  personal accessories  herbal products  food kiosks  upstream  bricks and blocks  stamping machine  hookah  fishing  breath fresheners  respiratory  neurology devices  petrochemicals  power tools  reservoir development  petroleum fuels  audio systems  specialty chemicals  polymer materials  process outsourcing  intelligence and analytics  artwork products  processed food  mro services  aerospace products  bone growth stimulators  midstream  baby equipment  rubber  equipments and services  airlines travel  electricity generation and transmission  fuel dispenser  refining  biopsy devices compare my shortlist compare my shortlist